SWM
VKTX icon

SHP Wealth Management’s Viking Therapeutics VKTX Stock Holding History

SHP Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21K Buy
31
+12
+63% +$388 ﹤0.01% 1541
2026
Q1 		$618 Buy
+19
New +$611 ﹤0.01% 1581

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

SHP Wealth Management's VKTX Position: Q2 2026 in Review

SHP Wealth Management increased its Viking Therapeutics (VKTX) stake by 63% in Q2 2026, buying an estimated $388 and bringing the position to 31 shares worth $1.21K. The position accounts for ﹤0.01% of the portfolio, ranked #1541.

SHP Wealth Management first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • SHP Wealth Management held 31 shares of Viking Therapeutics worth $1.21K as of Q2 2026.
  • SHP Wealth Management bought 12 Viking Therapeutics shares in Q2 2026, an estimated $388.
  • Viking Therapeutics made up ﹤0.01% of SHP Wealth Management's portfolio in Q2 2026, its #1541 holding.
  • SHP Wealth Management first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on SHP Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.